open access
Incidence and disease prevalence for lymphoid neoplasms in Poland


- Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland
- Department of Hematology, St. John’s Cancer Centre, Lublin, Poland
open access
Abstract
Abstract


Title
Incidence and disease prevalence for lymphoid neoplasms in Poland
Journal
Issue
Article type
Editorial
Pages
73-74
Page views
3263
Article views/downloads
280
DOI
10.5603/AHP.2022.0010
Bibliographic record
Acta Haematol Pol 2022;53(2):73-74.
Authors
Krzysztof Giannopoulos


- Lech-Marańda E, Budziszewska BK, Mikołajczyk T, et al. Incidence and prevalence of lymphatic neoplasms in Poland 2009–2015 determined on analysis of National Health Fund data used in the ‘Maps of healthcare needs — database of systemic and implementation analyses’ project. Acta Haematol Pol. 2022; 2(53): 1–2.
- Jurczak W, Walewski J. Mantle cell lymphoma — optimal therapy choice based on clinical trial results. Onkol Prakt Klin. 2007; 3(5): 254–258.
- Sant M, Allemani C, Tereanu C, et al. HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010; 116(19): 3724–3734.
- Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK's Haematological Malignancy Research Network. Br J Cancer. 2015; 112(9): 1575–1584.
- Surveillance, Epidemiology, and End Results (SEER) Program. National Cancer Institute, DCCPS, Surveillance Research Program, released December 2020. www.seer.cancer.gov (February 20, 2022).
- Dong Y, Shi O, Zeng Q, et al. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. 2020; 9: 14.
- https://ezdrowie.gov.pl/portal/home/zdrowe-dane/raporty/szpiczak-plazmocytowy (February 20, 2022).